Global capecitabine market is expected to reach 1031.47 million USD by 2022
The capecitabine is expected to decreased at a CAGR of 0.25% from 1047.30 million USD in 2016 to reach 1031.47 million USD by 2022 in global market. https://www.qyresearch.com/index/detail/293965/global-capecitabine-market
The capecitabine is expected to decreased at a CAGR of 0.25% from 1047.30 million USD in 2016 to reach 1031.47 million USD by 2022 in global market.
https://www.qyresearch.com/index/detail/293965/global-capecitabine-market
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Global</strong> <strong>capecitabine</strong> <strong>market</strong> <strong>is</strong><br />
<strong>expected</strong> <strong>to</strong> <strong>reach</strong> <strong>1031.47</strong><br />
<strong>million</strong> <strong>USD</strong> <strong>by</strong> <strong>2022</strong><br />
QYRESEARCH FOCUS ON MARKET SURVEY AND RESEARCH<br />
www.qyresearch.com
Beijing Hengzhou Bozhi International<br />
Information Consulting<br />
Web: qyresearchglobal.com | qyresearch.com<br />
TEL:+86-13660489419, Office:+86-2086655165<br />
Media: press@qyresearch.com<br />
Marketing: sales@qyresearch.com<br />
Facebook: @QYResearchOfficial,<br />
Twitter: @QYResearch_<br />
Wechat Official Account: QYResearch, Weibo: 恒 州 博 智<br />
www.qyresearch.com
QYResearch<br />
Capecitabine <strong>is</strong> an orally-admin<strong>is</strong>tered chemotherapeutic agent<br />
used in the treatment of metastatic breast and colorectal<br />
cancers. Capecitabine <strong>is</strong> a prodrug, which <strong>is</strong> enzymatically<br />
converted <strong>to</strong> fluorouracil (antimetabolite) in the tumor, where it<br />
inhibits DNA synthes<strong>is</strong> and slows growth of tumor t<strong>is</strong>sue.<br />
www.qyresearch.com
QYResearch<br />
The Capecitabine industry <strong>is</strong> highly concentrated, there are eight major manufactures in<br />
the world, and high-end products mainly come from North America and Western Europe.<br />
The <strong>capecitabine</strong> <strong>is</strong> <strong>expected</strong> <strong>to</strong> decreased at a CAGR of 0.25% from 1047.30 <strong>million</strong><br />
<strong>USD</strong> in 2016 <strong>to</strong> <strong>reach</strong> <strong>1031.47</strong> <strong>million</strong> <strong>USD</strong> <strong>by</strong> <strong>2022</strong> in global <strong>market</strong>.<br />
In the world wide, major manufactures mainly are Roche, Teva and Mylan.<br />
North America <strong>is</strong> the largest consumer of Capecitabine and <strong>is</strong> <strong>expected</strong> <strong>to</strong> retain the<br />
lowerr growth rate during the next five years.<br />
www.qyresearch.com
QYResearch<br />
China ave witnessed a major chunk of the production and consumption of<br />
Capecitabine in the Asia Pacific region. Actually, that <strong>is</strong> why manufacturers<br />
have several plants, usually close <strong>to</strong> aimed demand <strong>market</strong>.<br />
All manufactures in the world are committed <strong>to</strong> the improvement of product.<br />
These two years, some of Chinese and India manufactures can almost catch up<br />
with the world's leading technology <strong>to</strong>o. Most technologies are developed <strong>by</strong><br />
the manufacturers instead of importing from other companies.<br />
Click <strong>to</strong> view the full report:<br />
https://www.qyresearch.com/index/detail/293965/global-<strong>capecitabine</strong>-<strong>market</strong><br />
www.qyresearch.com
Change language